CLEO Diagnostics Ltd (AU:COV) has released an update.
CLEO Diagnostics Ltd, an Australian ovarian cancer diagnostics firm, reported strong progress in its March 2024 quarterly activities, including successful design transfer for prototype manufacturing and the publication of a peer-reviewed study demonstrating its test’s superior performance over the current CA125 standard. The company also launched strategic initiatives in the U.S. market, such as partnering with HcFocus for market access and reimbursement, and establishing a U.S. clinical trial managed by Lindus Health. With A$9.973M in cash reserves, CLEO is advancing in physician engagement in Australia and globally with its innovative blood test for early ovarian cancer detection.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
